S&P Revises FRHC Outlook to Positive, but Valuation Concerns Persist

What happened

S&P Global Ratings revised the outlook on Freedom Holding Corp. and its four core operating subsidiaries to positive from stable, while affirming their international credit ratings, signaling improved creditworthiness. The revision reflects S&P's view that Freedom's risk profile is improving, likely due to regulatory capital strength and potentially reduced sanctions or regulatory overhang that had previously weighed on the company. However, the DeepValue master report highlights that Freedom's equity story remains challenged: net income collapsed from ~$376 million in 2024 to ~$85 million in 2025, and the stock trades at over 165x trailing earnings with an ROE below 7%. Structural headwinds such as Kazakhstan's higher taxes, insurance commission caps, and concentration on a single market-maker continue to pressure earnings, while the company's telecom and media segments burn cash. While the positive outlook may lower funding costs and improve sentiment, it does not address the core issue of overvaluation relative to normalized earnings power, leaving the potential sell thesis intact.

Implication

Investors should treat the positive outlook as a credit rating development rather than a fundamental earnings catalyst. The equity continues to price in a rapid earnings recovery that may not materialize given persistent regulatory, tax, and concentration risks. The report's base case fair value remains near $105, implying ~20% downside from current levels, and the attractive entry is around $90. The positive outlook may reduce the probability of a credit downgrade, which could marginally lower discount rates, but it does not change the bearish scenario where cash flows remain volatile and losses in the Other segment continue. Until earnings normalize and regulatory uncertainties clear, maintaining a sell or avoid stance on strength is prudent.

Thesis delta

The S&P outlook revision to positive is a positive credit signal but does not alter the core equity thesis of overvaluation. The thesis remains a potential sell due to collapsed earnings, structural regulatory headwinds, and high concentration risk. The positive outlook may slightly reduce tail risk from funding or regulatory constraints, but it is insufficient to upgrade the recommendation or change the target price.